Skip to content
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate
TB Alliance | Putting science to work for better, faster TB cures.
  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • TB Market Access Research
    • Child-Friendly Medicines
    • Pretomanid and the BPaL Regimen
    • Access to the BPaL Regimen
  • News
    • News
    • Publications
    • Voices of TB
    • Research Papers
    • Innovate to Eradicate
Donate
Donate

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials

TB must be treated with multiple drugs to achieve maximal efficacy and prevent resistance. To transform treatment, novel TB regimens are needed. TB Alliance aims to register new drugs in combination with one another, or with existing TB drugs. The following regimens have been or currently are the subject of TB Alliance clinical trials.

BCZ

BCZPa

BPaL

BPaMZ

BPaZ

PaMZ

Pediatric HRZE

TBAJ-876 + pretomanid + linezolid

  • About
  • Why New TB Drugs
  • R&D
  • Access
  • News
New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328
Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org
Jobs

View job openings
Join our mailing list

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy